Evidence map›Paper›PMID 36937769›Full record

ReviewFrontiers in bioengineering and biotechnology2023

Self-assembling peptides as immunomodulatory biomaterials.

Andrea Hernandez, Jeffrey D Hartgerink, Simon Young

Full text readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A multidomain peptide hydrogel-liposome composite for controlled release of a cyclic dinucleotide in oral cancer.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Engineering the Immune Response to Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. An Overview of Supramolecular Platforms Boosting Drug Delivery.Bioinorganic chemistry and applications · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Andrea HernandezKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston, School of Dentistry, Houston, TX, United States.
Jeffrey D HartgerinkDepartment of Chemistry and Department of Bioengineering, Rice University, Houston, TX, United States.
Simon YoungKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston, School of Dentistry, Houston, TX, United States.

Funding

Self-assembling Peptide Nanofiber Hydrogels for Nerve RegenerationR01DE021798 · NIDCR · RICE UNIVERSITY · PI HARTGERINK, JEFFREY DALE · 2012 to 2021
$3.7M
SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local ImmunotherapyR01DE030140 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YOUNG, SIMON · 2021 to 2025
$3.0M
NIDCR NIH HHS R01 DE021798NIDCR NIH HHS R01 DE030140
6 · The paper itself

Abstract

Self-assembling peptides are a type of biomaterial rapidly emerging in the fields of biomedicine and material sciences due to their promise in biocompatibility and effectiveness at controlled release. These self-assembling peptides can form diverse nanostructures in response to molecular interactions, making them versatile materials. Once assembled, the peptides can mimic biological functions and provide a combinatorial delivery of therapeutics such as cytokines and drugs. These self-assembling peptides are showing success in biomedical settings yet face unique challenges that must be addressed to be widely applied in the clinic. Herein, we describe self-assembling peptides' characteristics and current applications in immunomodulatory therapeutics.

Indexed as

biomaterialscancerimmunotherapylocalized deliveryself-assembling peptides (SAP)

Identifiers

PMID36937769
PMCPMC10014862

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read7
reference markers read14
identifiers read6
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.